FRE Stock Overview
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Fresenius SE & Co. KGaA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €28.82 |
| 52 Week High | €30.00 |
| 52 Week Low | €28.82 |
| Beta | 1.1 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -34.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| FRE | BG Healthcare | BG Market | |
|---|---|---|---|
| 7D | 0% | -0.4% | 0.2% |
| 1Y | n/a | -7.2% | 17.0% |
Return vs Industry: Insufficient data to determine how FRE performed against the BG Healthcare industry.
Return vs Market: Insufficient data to determine how FRE performed against the BG Market.
Price Volatility
| FRE volatility | |
|---|---|
| FRE Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 4.9% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in BG Market | 8.5% |
| 10% least volatile stocks in BG Market | 2.4% |
Stable Share Price: FRE has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine FRE's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1912 | 193,527 | Michael Sen | www.fresenius.com |
Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.
Fresenius SE & Co. KGaA Fundamentals Summary
| FRE fundamental statistics | |
|---|---|
| Market cap | €14.62b |
| Earnings (TTM) | €941.00m |
| Revenue (TTM) | €41.60b |
15.5x
P/E Ratio0.4x
P/S RatioIs FRE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FRE income statement (TTM) | |
|---|---|
| Revenue | €41.60b |
| Cost of Revenue | €31.09b |
| Gross Profit | €10.51b |
| Other Expenses | €9.57b |
| Earnings | €941.00m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Mar 14, 2024
| Earnings per share (EPS) | 1.67 |
| Gross Margin | 25.27% |
| Net Profit Margin | 2.26% |
| Debt/Equity Ratio | 43.0% |
How did FRE perform over the long term?
See historical performance and comparison